Moderna Gets Clearance To Deliver Spikevax COVID-19 Vaccine In Canada
Synopsis
The company said that it is on track to deliver the updated vaccine in the Canadian market in time for the 2025-2026 vaccination season.
Moderna announced on Friday that its updated COVID-19 mRNA vaccine, Spikevax, has received authorization in Canada for those aged six months and older.
The company said that it is on track to deliver the updated vaccine in the Canadian market in time for the 2025-2026 vaccination season. The firm added that the pre-filled syringe doses of the vaccine for the market will be made domestically. While the drug substance will be produced at the company’s facility in Laval, Quebec, fill-finish operations will be completed by Novocol Pharma in Cambridge, Ontario.
Get updates to this developing story <directly on Stocktwits.<
Stay updated with all the latest Business News, including market trends, Share Market News, stock updates, taxation, IPOs, banking, finance, real estate, savings, and investments. Track daily Gold Price changes, updates on DA Hike, and the latest developments on the 8th Pay Commission. Get in-depth analysis, expert opinions, and real-time updates to make informed financial decisions. Download the Asianet News Official App from the Android Play Store and iPhone App Store to stay ahead in business.